2025.Dec.19
The Company’s BOD resolved to enter into commercial licensing agreement with TegMine for the development of glycoprotein monoclonal antibody ADC
Date of occurrence of the event:2025/12/19 Counterparty to the contract or commitment: TegMine Therapeutics, Inc. (hereinafter referred to as “TegMine”) Relationship with the Company:None Starting and ending dates (or rescission date) of the contract or commitment:Starting from the effective date of the agreement until the expiration date of the relevant patents. Major content (not applicable […]
This article is password protected.
To view the content, please enter your password in the field below